
The FDA approves oral SERD giredestrant for ESR1-mutated breast cancer after a 62% risk cut, tying supply to testing ahead of a November 30, 2026 adjuvant decision.
The authors examine the development and performance of coprocessed excipients, including testing them for flowability, compressibility, amd dilution potential.
almost 23 years ago
Manufacturing Execution Systemsalmost 23 years ago
State-of-the-Art Packaging Machinesalmost 23 years ago
January 2004almost 23 years ago
Medicare Bill Contains Significant Changes for Drug Manufacturersalmost 23 years ago
The Bioterrorism Actalmost 23 years ago
New Supply-Chain Dynamicsalmost 23 years ago
In the Spotlight--February 2004almost 23 years ago
January 2004





